[Proliferation signal inhibitors: what therapeutic protocols are followed in 2009?]

Area of Science:

• Nephrology
• Immunosuppression
• Transplantation

Context:

• Proliferation signal inhibitors (PSI) have been utilized in France for kidney transplantation for approximately a decade.
• These agents offer benefits such as anti-proliferation, anti-tumor properties, and lack of nephrotoxicity, contributing to long-term kidney function preservation in transplant patients.
• Their application has been explored in therapeutic strategies to mitigate the nephrotoxicity associated with calcineurin inhibitors (CNI).

Purpose:

• To evaluate the efficacy of PSI in kidney transplant recipients.
• To assess strategies involving CNI minimization and therapy switching to PSI for improved kidney function.
• To identify predictors of successful outcomes in such therapeutic regimens.

Summary:

• Therapeutic regimens minimizing calcineurin inhibitor (CNI) use and incorporating switches to proliferation signal inhibitors (PSI) between 3 and 6 months post-transplant demonstrate positive outcomes.
• These strategies are particularly effective in preventing the deterioration of kidney function.
• Key predictors of success include the preservation of good kidney function and the absence of proteinuria, although the optimal timing for switching therapies requires further definition.

Impact:

• These findings suggest that PSI-based regimens can be a valuable option for managing kidney transplant patients, especially those with or at risk of CNI toxicity.
• The approach aids in preserving long-term kidney function and may be considered in cases of de novo cancer development.
• Further research into the precise timing of therapy switches can optimize patient outcomes and enhance the long-term success of kidney transplantation.